H.A. Chaudri - Concepedia

Author

H.A. Chaudri

Novartis (Switzerland)

Also Known As

H A Chaudri, H. A. Chaudri, H. Chaudri, H.A Chaudri, H.A. Chaudri, HILARY A. CHAUDRI, Hilary A. Chaudri

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)

About

H.A. Chaudri is an author at Novartis (Switzerland) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	379
2	Health Sciences	2	2	60
3	Social Sciences	1	1	16
4	Epidemiology	1	1	16
5	Immunology	1	1	19

H.A. Chaudri

Publications

Citations

H-Index

Page 1

	Year	Citations
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. P Dombernowsky, I E Smith, Geoffrey Falkson, Journal of Clinical Oncology	1998	640
Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer M. Gershanovich, H.A. Chaudri, Diogo Ayres‐de‐Campos, Annals of Oncology Advanced Breast CancerBreast OncologyOncologyMedicineAromatase	1998	263
Report on a Long-Term Tolerability Study of Up to Two Years with Diclofenac Sodium (Voltaren) S N Ciccolunghi, H.A. Chaudri, B I Schubiger, Scandinavian Journal of Rheumatology Electrolyte DisorderPharmacotherapyOrthopaedic SurgeryInflammatory ArthritisRheumatoid Disorder	1978	45
Clinical use of aromatase inhibitors in the treatment of advanced breast cancer Patrick Trunet, Franzanne Vreeland, Catherine Royce, The Journal of Steroid Biochemistry and Molecular Biology Advanced Breast CancerBreast OncologyOncologyMedicineAromatase	1997	21
Interleukin-6 induction by a muramyltripeptide derivative in cancer patients. Heiner Frost, James L. Murray, H.A. Chaudri, PubMed InflammationCytokineAutoimmune DiseaseMedicineImmunology	1990	19
A Methodological Study of Some Factors Influencing the Reporting of Symptoms S N Ciccolunghi, H.A. Chaudri The Journal of Clinical Pharmacology Spontaneous OccurrenceDiagnosisSomatic Symptom DisorderAnalyzable QuestionnaireMental Health	1975	16
PP-8-3 Double-blind trial in postmenopausal (PMP) women with advanced breast cancer (ABC) showing a dose-effect and superiority of 2.5 mg letrozole over megestrol acetate (MA) I. E. Smith, P. Dombemowsky, Geoffrey Falkson, European Journal of Cancer Megestrol AcetateAdvanced Breast CancerOncologyPp-8-3 Double-blind TrialBreast Oncology	1996	15
The value and results of long-term studies with diclofenac sodium (Voltarol). S N Ciccolunghi, H.A. Chaudri, B I Schubiger PubMed	1979	11

Page 1